Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 16/20 | 0.41 |
| ▸ | MC5R | P33032 | 14/20 | 0.41 |
| ▸ | MC3R | P41968 | 11/20 | 0.41 |
| ▸ | MC1R | Q01726 | 9/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324336 | 0.93 | MC4R (0.40) | MC4RMC5RMC3RMC1RHTT | |
| SCHEMBL1324578 | 0.92 | MC4R (0.49) | MC4RMC5RMC3RMC1R | |
| SCHEMBL1325370 | 0.92 | MC4R (0.47) | MC4RMC5RMC3RMC1R | |
| SCHEMBL1309343 | 0.90 | MC4R (0.44) | MC4RMC5RMC3RMC1R | |
| SCHEMBL15016822 | 0.90 | MC4R (0.44) | MC4RMC5RMC3RMC1R | |
| SCHEMBL1325270 | 0.88 | KMT2A (0.39) | MC4RMC5RMC3RMC1RKMT2A | |
| SCHEMBL2364150 | 0.88 | REN (0.42) | MC4RMC5RMC3RMC1RKMT2A | |
| SCHEMBL1311389 | 0.87 | MC4R (0.43) | MC4RMC5RMC3RMC1RKMT2A | |
| SCHEMBL15272893 | 0.86 | MC4R (0.44) | MC4RMC5RMC3RMC1RKMT2A | |
| SCHEMBL1309703 | 0.86 | MC4R (0.44) | MC4RMC5RMC3RMC1RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962846-B2 | Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-24 | — | — | US | claimed |
| US-20110281913-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-17 | — | — | US | claimed |
| EP-2352729-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2011-08-10 | — | — | EP | claimed |
| WO-2010052256-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | claimed |
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-11-19 | — | — | US | disclosed |
| US-8962846-B2 | Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2352729-B1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-14 | — | — | EP | disclosed |
| WO-2012131090-A1 | METHOD FOR TREATMENT OF XERODERMA PIGMENTOSUM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-04 | — | — | WO | disclosed |
| US-20110281913-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-17 | — | — | US | disclosed |
| EP-2352729-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010052256-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | MC4R 4/4885MC5R 2/4885MC3R 3/4885 |
| US-20110281913-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | MC4R 4/4885MC5R 2/4885MC3R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.